Background: Ewing sarcoma and desmoplastic small round cell tumors (DSRCT) are rare and
TA B L E 1 KDM1A inhibitors
NA NA of genomic regions and creating de novo enhancer elements that establish the Ewing sarcoma transcriptional signature. [8] [9] [10] In particular, the nucleosome remodeling deacetylase complex (NuRD; also known as Mi-2), a multi-subunit chromatin-remodeling complex commonly associated with repression of transcriptional activity, was identified to be relevant in the silencing of EWS-FLI1 target genes. 10, 11 Essentially, the catalytic activity in the NuRD complex involves deacetylation by histone deacetylase 2 (HDAC2) and 3 (HDAC3), coupled with demethylation by lysine-specific demethylase 1 (KDM1A; also referred to as LSD1, AOF2, and BHC110). 9, 10 The working model proposed by Sankar et al consists of EWS-FLI1 binding to promoters of repressed target genes, followed by the recruitment of the NuRD complex through interaction between its subunits chromodomain 4 (CHD4) and metastasis-associated protein 1 (MTA1) and the EWS portion of the fusion protein. Following treatment with SP2509, a tool compound targeting KDM1A, the EWS-FLI1-driven transcriptional signature of both upregulated and downregulated genes was reversed. 10 Inhibition of KDM1A with SP2509 also resulted in apoptosis and disruption of the oncogenic phenotype. 10 KDM1A is a well-characterized histone lysine demethylase belonging to the family of flavin-dependent amine oxidases that has an important role in stem cell maintenance through transcriptional repression. [12] [13] [14] This demethylase is also overexpressed in Ewing sarcoma and other sarcomas including DSRCT and rhabdomyosarcoma. [15] [16] [17] Moreover, the key role of the EWS portion of the fusion protein in the interaction with repressive chromatinremodeling complexes makes inclusion of DSRCT, possessing the EWS-WT1 fusion, relevant to study alongside EWS-FLI1 in Ewing sarcoma. 8, 9 Currently, the KDM1A inhibitor ORY-1001 is being investigated in the clinic in adult patients with acute myeloid leukemia (AML) and small cell lung cancer (SCLC). In addition, a trial with GSK2879552
has recently been stopped citing that the benefits do not outweigh the risk in relapsed refractory SCLC [18] [19] [20] [21] (Table 1) . These compounds are potent irreversible inhibitors of KDM1A, which covalently modify the FAD cofactor of this demethylase to inhibit catalytic activity. 22, 23 However, their use as a therapeutic strategy for Ewing sarcoma has not been comprehensively assessed. Given the rationale for targeting KDM1A in Ewing sarcoma, in this work, we sought to test the potential for repurposing these clinical candidates against KDM1A as a novel treatment for these sarcomas.
The current report investigates the effect of catalytic inhibitors of KDM1A on cell viability in 2D and 3D models, and invasion using a 3D spheroid assay. Importantly, we show that clinically available inhibitors of KDM1A catalytic demethylase activity, despite having an effect on viability at a low nanomolar range against leukemia cell lines, do not have an effect in preclinical models of Ewing sarcoma and DSRCT.
Therefore, catalytic inhibition of KDM1A should not be considered as a therapeutic strategy for Ewing sarcoma. 
METHODS

Cell lines
Reagents and drug treatments
The following KDM1A inhibitors were used: ORY-1001, GSK2879552, GSK-LSD1, and SP2509 (Table 1 ; SelleckChem, UK). Stocks (10 mM)
were prepared in H 2 O for ORY-1001 and GSK2879552, and in DMSO for GSK-LSD1 and SP2509 and stored at −80 • C. For MV(4;11) and MOLT-4 viability assays, cells were seeded at 100 000/well (6-well plate) and cultured for the indicated time. Viable cell counts were determined by Trypan blue assay (Sigma-Aldrich, UK).
Cell viability assays
3D spheroid culture
Three-dimensional spheroids were generated and cultured using the GravityTRAP ULA Plate 96-well (PerkinElmer, UK) unless otherwise indicated. Prior to seeding, wells were pre-wet with 40 L of medium.
One thousand cells in 70 L were seeded into each well. Plates were spun for two minutes at 250 RCF to remove trapped air bubbles. Routine medium changes were performed every 48 hours by carefully aspirating the medium from the ledge at the inside wall of the well and replenishing it with fresh medium.
Image analysis of 3D spheroids
Digital images of spheroids were captured throughout the duration of the experiments using an IN Cell Analyzer 2200 imaging system (GE Healthcare Life Sciences, UK), and the surface area was assessed at the focal plane with maximum diameter with IN Cell Investigator IN Developer Toolbox (GE Healthcare Life Sciences).
Western blot analysis 2.6.1 H3K4me2 immunoblot
Following treatment, 2. were taken every hour to monitor invasion.
qRT-PCR
RNA was extracted with TRIzol according to the manufacturer's protocol. 25 Hs00971716_m1. Human RPLPO endogenous control (Applied Biosystems, CA, USA) was used to normalize gene expression.
Statistical analysis
GraphPad PRISM 7 and R studio 3. Dunnett test and Sidak test where applicable. P < 0.05 was considered significant and indicated by *, P < 0.01 is indicated by **, P < 0.001 is indicated by ***, and P < 0.0001 is indicated by ****.
RESULTS
Presently, there is no evidence demonstrating whether the clinical drug Figure S1A ). 9, 10 These effects were replicated in the DSRCT cell line, only showing sensitivity to SP2509 and not to the clinical drug candidates ( Figure S1B ).
To address the discrepancy between the KDM1A inhibitors, a chemical probe validated as a potent and selective inhibitor of KDM1A catalytic demethylase activity (GSK-LSD1) was also tested in these sarcoma cell lines (http://www.thesgc.org/chemical-probes/LSD1). 23, 26 Again, treatment had no meaningful effect on cell viability, with only a 50% reduction at 10 M in one cell line (TC71; Figure 1 ; Supporting Information Figure S1C ). KDM1A protein levels were unaffected following treatment with clinical drug candidates ORY-1001 and GSK2879552 after 48, 72, 96, and 168 hours (Supporting Information Figure S1D -S1E).
Importantly, consistent with their in vitro inhibition of KDM1A demethylase activity, all four compounds were able to modulate KDM1A-mediated demethylation of the H3K4 methyl mark, a wellcharacterized KDM1A substrate. 15 Figure   S1F -S1H), 9,10 possibly due to the lower concentration used in our experiments.
To further demonstrate compound activity, we assessed the response of leukemia cells, previously shown to be sensitive to inhibition of KDM1A catalytic function by ORY-1001 in the nanomolar range. 22 In agreement with published findings, the clinical candidate ORY-1001, as well as chemical probe GSK-LSD1, showed a reduction in cell viability upon treatment with compound at 10 nM concentrations in two leukemia cell lines (Supporting Information Figure S2A and S2B). The clinical candidate GSK2879552 also decreased cell viability at 2 M (Supporting Information Figure S2C ).
To perform a more comprehensive evaluation of the effect of KDM1A inhibition, assessment of cell viability experiments was expanded to 3D models of Ewing sarcoma. Three-dimensional cell culture systems have become more prominent in preclinical studies due to their ability to more closely represent tissue compartments and enable longer experimental time frames. 27 Tumor spheroids, for example, can recapitulate aspects of the tumor microenvironment that ultimately influence drug response. 28 A673 spheroid cultures were treated with ORY-1001 and SP2509 for 10 days with a dose range between 0.3 and 10 M (Figure 2 and 2B) . Again, no effect on growth was observed with the irreversible inhibitor of KDM1A catalytic function ORY-1001, whereas SP2509 was active, albeit at higher concentrations compared with 2D cultures (Figure 2 and 2B) . Drugs targeting epigenetic modifying enzymes often require prolonged inhibition for maximal drug potency and response to treatment. 22, 23, 29 We therefore additionally treated spheroids for up to 21 days with a maximum concentration of 100 M of both clinical candidates (ORY-1001 and GSK2879552).
Both clinical candidates had no effect upon spheroid growth (Figure 2 and 2E), even in the extended assay.
Finally, KDM1A has been reported to have a role in migration and invasion. 30 To complete the phenotypic assessment of KDM1A inhi- Figure S3 ). Again, we included the chemical probe GSK-LSD1 in the assay; it also had no effect on invasion (Figure 3 and 3B;
Supporting Information Figure S3 ).
DISCUSSION
The Ewing sarcoma gene-expression profile heavily relies on EWS-FLI1 coordinating vast epigenetic rewiring through the recruitment and activity of chromatin-remodeling complexes. 7, 8, 31 In this context, KDM1A, an active subunit of the NuRD complex, has been reported to have an important role in repressing and activating target genes of the fusion protein EWS-FLI1. 9, 10 The functional role of KDM1A
in Ewing sarcoma oncogenesis, alongside high expression in this and other sarcomas such as DSRCT, has made it a promising therapeutic target. 32, 33 In light of this, our aim was to assess the therapeutic potential of KDM1A inhibitors (ORY-1001 and GSK2879552) in Ewing sarcoma models.
Global or promoter-specific accumulation of methylation of H3K4
is not always seen following KDM1A inhibition regardless of decreased KDM1A activity. 23, 34 However, in our findings, the global change in confirming their dependency on this demethylase. 38 The discrepancy between our results through inhibition of KDM1A catalytic function and knockdown of the multidomain protein strongly suggests a noncanonical role for KDM1A, independent from its demethylase function.
These characteristics coincide with other epigenetic regulators such as EZH2. Its emerging methyltransferase-and polycomb-independent roles provide novel therapeutic potential for inhibitors disrupting its docking capacity. 39 In line with this model, recent reports in prostate cancer cell lines described a scaffolding role for KDM1A, whereby catalytically inactive KDM1A was still able to establish the prostate cancer gene network and ensure survival of castration-resistant prostate cancer cell lines. 40 This was further confirmed with the tool compound SP2509, proposed as an allosteric inhibitor binding to the H3 pocket region of KDM1A, capable of inducing cell death in prostate cancer cell lines. Similarly, this could also explain the previously observed reversal of the EWS-FL1 signature effects with SP2509 in Ewing sarcoma cells. 10 However, it is noteworthy that SP2509 has been shown to effectively cause cell death regardless of KDM1A expression in a leukemia KDM1A knockout cell line and its isogenic control. 41 In addition to disrupting KDM1A's complex formation capabilities, SP2509 may have additional cytotoxic effects independent from KDM1A binding. Consistent with this, 2-hydroxyphenyl-hydrazone structural motif within SP2509 has previously been identified as a pan-assay interference flag and has the potential to elicit promiscuous biological activity. [42] [43] [44] KDM1A's role as a docking element for additional proteins may play a more prominent part in Ewing sarcoma cells survival than previously considered. 15 Our work is particularly timely and pertinent as a drug of the same mechanistic class of KDM1A inhibitors as the irreversible KDM1A demethylase inhibitors tested here has entered phase I trials in Ewing sarcoma patients (NCT03514407). In summary, we demonstrate that the clinical candidates ORY-1001 and GSK2879552, which act predominantly as inhibitors of KDM1A catalytic function, are not effective against in vitro models of Ewing sarcoma. The data presented here do not support clinical trials exploring inhibition of KDM1A demethylase function as a therapeutic strategy for the treatment of Ewing sarcoma and DSRCT.
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